Equilibrative nucleotide transporter ENT3 (SLC29A3) : A unique transporter for inherited disorders and cancers
Copyright © 2023 Elsevier Inc. All rights reserved..
As a crucial gene associated with diseases, the SLC29A3 gene encodes the equilibrative nucleoside transporter 3 (ENT3). ENT3 plays an essential regulatory role in transporting intracellular hydrophilic nucleosides, nucleotides, hydrophilic anticancer and antiviral nucleoside drugs, energy metabolism, subcellular localization, protein stability, and signal transduction. The mutation and inactivation of SLC29A3 are intimately linked to the occurrence, development, and prognosis of various human tumors. Moreover, many hereditary human diseases, such as H syndrome, pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome, Faisalabad histiocytosis (FHC), are related to SLC29A3 mutations. This review explores the mechanisms of SLC29A3 mutations and expression alterations in inherited disorders and cancers. Additionally, we compile studies on the inhibition of ENT3, which may serve as an effective strategy to potentiate the anticancer activity of chemotherapy. Thus, the synopsis of genetics, permeant function and drug therapy of ENT3 provides a new theoretical and empirical foundation for the diagnosis, prognosis of evaluation and treatment of various related diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:434 |
|---|---|
| Enthalten in: |
Experimental cell research - 434(2024), 2 vom: 15. Jan., Seite 113892 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Hongying [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 10.01.2024 Date Revised 19.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.yexcr.2023.113892 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365953458 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365953458 | ||
| 003 | DE-627 | ||
| 005 | 20240119231952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.yexcr.2023.113892 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1264.xml |
| 035 | |a (DE-627)NLM365953458 | ||
| 035 | |a (NLM)38104646 | ||
| 035 | |a (PII)S0014-4827(23)00443-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Hongying |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Equilibrative nucleotide transporter ENT3 (SLC29A3) |b A unique transporter for inherited disorders and cancers |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.01.2024 | ||
| 500 | |a Date Revised 19.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a As a crucial gene associated with diseases, the SLC29A3 gene encodes the equilibrative nucleoside transporter 3 (ENT3). ENT3 plays an essential regulatory role in transporting intracellular hydrophilic nucleosides, nucleotides, hydrophilic anticancer and antiviral nucleoside drugs, energy metabolism, subcellular localization, protein stability, and signal transduction. The mutation and inactivation of SLC29A3 are intimately linked to the occurrence, development, and prognosis of various human tumors. Moreover, many hereditary human diseases, such as H syndrome, pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome, Faisalabad histiocytosis (FHC), are related to SLC29A3 mutations. This review explores the mechanisms of SLC29A3 mutations and expression alterations in inherited disorders and cancers. Additionally, we compile studies on the inhibition of ENT3, which may serve as an effective strategy to potentiate the anticancer activity of chemotherapy. Thus, the synopsis of genetics, permeant function and drug therapy of ENT3 provides a new theoretical and empirical foundation for the diagnosis, prognosis of evaluation and treatment of various related diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a ENT3 | |
| 650 | 4 | |a Inherited disorders | |
| 650 | 4 | |a SLC29A3 | |
| 650 | 7 | |a Nucleotides |2 NLM | |
| 650 | 7 | |a Membrane Transport Proteins |2 NLM | |
| 650 | 7 | |a SLC29A3 protein, human |2 NLM | |
| 650 | 7 | |a Nucleoside Transport Proteins |2 NLM | |
| 700 | 1 | |a Qu, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Yongkang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Linxin |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Yiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Weixin |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Yuxin |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Zicheng |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Qiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental cell research |d 1953 |g 434(2024), 2 vom: 15. Jan., Seite 113892 |w (DE-627)NLM000003123 |x 1090-2422 |7 nnns |
| 773 | 1 | 8 | |g volume:434 |g year:2024 |g number:2 |g day:15 |g month:01 |g pages:113892 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.yexcr.2023.113892 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 434 |j 2024 |e 2 |b 15 |c 01 |h 113892 | ||